TTR and AL amyloidosis: Disease-modifying therapies based on the pathophysiology of amyloidosis, which include chemotherapeutic agents against plasma cell dyscrasia for AL amyloidosis, gene silencing agents to knockdown TTR for ATTR amyloidosis, and monoclonal antibodies against proinflammatory cytokines for AA amyloidosis, have now become available [7,10,59,60].